Please login to the form below

Not currently logged in
Email:
Password:

Nucala

This page shows the latest Nucala news and features for those working in and with pharma, biotech and healthcare.

Dermira craters as acne drug fails late-stage test

Dermira craters as acne drug fails late-stage test

s IL-4 and IL-13-targeting drug Dupixent (dupilumab), Pfizer’s new topical treatment Eucrisa (crisaborole) and potentially other drugs such as GlaxoSmithKline’s asthma drug Nucala (mepolizumab), which is

Latest news

  • AZ gets EMA green light for severe asthma drug Fasenra AZ gets EMA green light for severe asthma drug Fasenra

    AZ gets EMA green light for severe asthma drug Fasenra. The biologic respiratory treatment will go up against GSK’s Nucala and Teva’s Cinqaero. ... Fasenra (benralizumab) is the third IL-5-targetting drug approved for market after GlaxoSmithKline’s

  • GSK gets another approval for Nucala in US GSK gets another approval for Nucala in US

    GSK gets another approval for Nucala in US. Its antibody is first approved treatment for a rare and sometimes life-threatening vascular disease. ... The FDA has approved GlaxoSmithKline’s IL-5 blocker Nucala for a rare and sometimes life-threatening

  • EMA approves GSK’s triple COPD therapy EMA approves GSK’s triple COPD therapy

    GSK could also have a winner on its hands if severe asthma therapy Nucala (mepolizumab) - an IL-5 inhibitor - also gets regulatory approval in COPD.

  • AZ prices severe asthma drug Fasenra below competition AZ prices severe asthma drug Fasenra below competition

    AZ is also emphasising the drug’s maintenance dosing frequency of every eight weeks, whereas Nucala and Cinqair require monthly doses. ... Like Nucala it is administered by subcutaneous injections while Cinqaero requires an intravenous infusion.

  • AZ severe asthma drug benralizumab backed by CHMP AZ severe asthma drug benralizumab backed by CHMP

    AZ is vying to make the drug the third IL-5 inhibitor to reach the market for severe asthma after GlaxoSmithKline’s Nucala (mepolizumab) and Teva's Cinqaero (reslizumab), and says ... Nucala has got off to a fair start in the market, bringing in £213m

More from news
Approximately 13 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • The good, the bad and the ugly The good, the bad and the ugly

    Its revenues grew by a further 9% last year. “A large percentage of this growth was driven by Ellipta, but Nucala - a biologic approved for asthma and COPD - also played its

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PharmiWeb Solutions

PharmiWeb Solutions creates, delivers and manages digital solutions for the pharmaceutical and healthcare segment. From digital marketing, to patient education...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics